Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Dalvance, Xydalba

Dalbavancin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Dalbavancin (also known as Dalvance) is a peptide catalogued under Cyclic & Antimicrobial (Lipoglycopeptide). It is described as: Cell wall synthesis. Documented context: Acute bacterial skin infections. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Dalbavancin?

Dalbavancin (brand names Dalvance in the US, Xydalba in the EU) is a semisynthetic lipoglycopeptide antibiotic derived from a teicoplanin-class precursor, FDA-approved in 2014 and EMA-approved for acute bacterial skin and skin-structure infections (ABSSSI) caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA).

Its defining feature is an ultra-long terminal half-life (roughly 8.5 to 15 days) that enables a complete course as either a two-dose regimen (1000 mg followed by 500 mg one week later) or a single 1500 mg infusion.

Evidence level is high: efficacy rests on two pivotal, well-powered phase 3 non-inferiority randomized controlled trials (DISCOVER 1 and 2) plus a subsequent single-dose versus two-dose RCT, all in humans.

How does Dalbavancin work?

Dalbavancin binds the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation and thereby inhibiting bacterial cell-wall synthesis; its lipophilic side chain anchors it in the membrane, prolonging activity.

It is bactericidal against Gram-positive pathogens including staphylococci (MRSA) and streptococci.

What does the research say about Dalbavancin?

  • Once-weekly dalbavancin was non-inferior to twice-daily vancomycin (with optional oral linezolid) for ABSSSI in the pooled DISCOVER 1 and 2 phase 3 trials. [1]
  • A single 1500 mg infusion was non-inferior to the two-dose regimen, supporting complete one-visit therapy for ABSSSI. [2]
  • In a pooled post hoc analysis, dalbavancin showed lower nephrotoxicity rates than vancomycin across three trials. [3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Once-weekly dalbavancin versus daily conventional therapy for skin infection — Boucher HW et al., The New England Journal of Medicine 2014. (Phase 3 RCT (DISCOVER 1 and 2))
  • [2] A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection — Dunne MW et al., Clinical Infectious Diseases 2016. (Phase 3b RCT)
  • [3] Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials — Gonzalez PL et al., Infectious Diseases and Therapy 2021. (Pooled post hoc safety analysis)
  • [4] Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic — Dash RP et al., Infectious Diseases (London) 2017. (Pharmacokinetic review)
  • [5] The role of dalbavancin in skin and soft tissue infections — Bassetti M et al., Current Opinion in Infectious Diseases 2018. (Narrative review)
  • [6] Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance — Zeng D et al., Cold Spring Harbor Perspectives in Medicine 2016. (Mechanistic review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the trials and labeling, dalbavancin is given intravenously as either 1000 mg then 500 mg one week later, or a single 1500 mg dose, infused over 30 minutes.

This context is descriptive of the regulated indication only and is not medical advice or a recommendation for any unapproved use.

Side effects & safety profile

The most common adverse reactions in trials were nausea, headache, and diarrhea, and dalbavancin was generally well tolerated with nephrotoxicity rates lower than vancomycin in a pooled analysis.

Because clearance is slow, an adverse reaction cannot be quickly reversed by stopping the drug; rapid infusion has been associated with red-man-type reactions and dose adjustment is advised in severe renal impairment (creatinine clearance under 30 mL/min) without regular hemodialysis.

Hypersensitivity and, rarely, ALT elevations have been reported; there is potential cross-reactivity with other glycopeptides.

Stacking & combinations

Dalbavancin is used as monotherapy for its labeled ABSSSI indication and is not intended to be combined with other agents outside clinician-directed care.

Finding Dalbavancin vendors

Finding Dalbavancin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is FDA- and EMA-approved for acute bacterial skin and skin-structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including MRSA.

References

  1. [1] Once-weekly dalbavancin versus daily conventional therapy for skin infection — Boucher HW et al., The New England Journal of Medicine 2014. PMID: 24897082. View sourceStudy: Phase 3 RCT (DISCOVER 1 and 2)Once-weekly dalbavancin was non-inferior to conventional daily therapy for ABSSSI.
  2. [2] A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection — Dunne MW et al., Clinical Infectious Diseases 2016. PMID: 26611777. View sourceStudy: Phase 3b RCTA single 1500 mg dose was non-inferior to the two-dose regimen for ABSSSI.
  3. [3] Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials — Gonzalez PL et al., Infectious Diseases and Therapy 2021. PMID: 33515414. View sourceStudy: Pooled post hoc safety analysisDalbavancin was associated with lower nephrotoxicity rates than vancomycin.
  4. [4] Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic — Dash RP et al., Infectious Diseases (London) 2017. PMID: 28264598. View sourceStudy: Pharmacokinetic reviewDescribes the ultra-long half-life underpinning single-dose and once-weekly dosing.
  5. [5] The role of dalbavancin in skin and soft tissue infections — Bassetti M et al., Current Opinion in Infectious Diseases 2018. PMID: 29298166. View sourceStudy: Narrative reviewPositions dalbavancin within ABSSSI management including outpatient use.
  6. [6] Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance — Zeng D et al., Cold Spring Harbor Perspectives in Medicine 2016. PMID: 27663982. View sourceStudy: Mechanistic reviewDetails D-Ala-D-Ala binding and cell-wall inhibition shared by lipoglycopeptides.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.